Top Suppliers:I want be here


1215281-19-8

1215281-19-8 structure
1215281-19-8 structure
  • Name: YK 3-237
  • Chemical Name: {2-Methoxy-5-[(1E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propen-1-yl]phenyl}boronic acid
  • CAS Number: 1215281-19-8
  • Molecular Formula: C19H21BO7
  • Molecular Weight: 372.177
  • Catalog: Signaling Pathways Cell Cycle/DNA Damage Sirtuin
  • Create Date: 2018-07-05 01:24:58
  • Modify Date: 2024-01-11 20:26:41
  • YK-3-237, a SIRT1 activator, targets mutant p53. YK-3-237 inhibits the proliferation of triple-negative breast cancer cells[1].

Name {2-Methoxy-5-[(1E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propen-1-yl]phenyl}boronic acid
Synonyms MFCD28167612
Boronic acid, B-[2-methoxy-5-[(1E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propen-1-yl]phenyl]-
{2-Methoxy-5-[(1E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propen-1-yl]phenyl}boronic acid
Description YK-3-237, a SIRT1 activator, targets mutant p53. YK-3-237 inhibits the proliferation of triple-negative breast cancer cells[1].
Related Catalog
Target

SIRT1

In Vitro YK-3-237 exhibits the anti-proliferative activities toward most of the breast cancer cell lines tested at submicromolar concentration. YK-3-237 preferentially inhibits the proliferation of breast cancer cell lines carrying mtp53[1]. YK-3-237 inhibits the proliferation of triple-negative breast cancer (TNBC) HS578T, MDA-MB-453, SUM1315MO2, SUM149PT, BT549, MDA-MB-231, MDA-MB-436, MDA-MB-468, HCC1937 with IC50s of 0.160±0.043, 0.241±0.086, 0.253±0.028, 0.289±0.066, 0.353±0.017, 0.431±0.136, 0.501±0.062, 1.436±0.754, 5.031±2.010 µM, respectively[1]. YK-3-237 inhibits the proliferation of Luminal T47D, MCF7, and ZR-75-1 with IC50s of 1.573±0.370, 2.402±0.256, 3.822±0.967 µM, respectively[1]. YK-3-237 inhibits the proliferation of HER2 BT474 and SK-BR-3 with IC50s of 1.249±0.372 and 0.346±0.066 µM, respectively[1]. YK-3-237 (0.01-10 µM; 24 hours) deacetylates mtp53 in TNBC cell lines[1]. YK-3-237 is a potent activator of Sirt1, on the activation of renal interstitial fibroblasts using NRK-49F cells[2]. Exposure of cells to YK-3-237 also significantly reduces expression of α-SMA and fibronectin in a dose-dependent manner, with the maximum inhibition occurring at 10 μM[2]. Cell Viability Assay[1] Cell Line: BT549, MDA-MB-468, HS578T, SUM149PT Concentration: 0, 0.01, 0.03, 0.1, 0.3, 1, 3, 10 µM Incubation Time: 24 hours Result: Reduced both the acetylation of K382 and the level of mtp53 in a dose-dependent manner in mtp53 TNBC cell lines.
References

[1]. Yong Weon Yi, et al. Targeting mutant p53 by a SIRT1 activator YK-3-237 inhibits the proliferation of triple-negative breast cancer cells. Oncotarget. 2013 Jul;4(7):984-94.

[2]. Murugavel Ponnusamy, et al. Activation of Sirtuin-1 Promotes Renal Fibroblast Activation and Aggravates Renal Fibrogenesis. J Pharmacol Exp Ther. 2015 Aug;354(2):142-51.

Density 1.3±0.1 g/cm3
Boiling Point 616.2±65.0 °C at 760 mmHg
Molecular Formula C19H21BO7
Molecular Weight 372.177
Flash Point 326.5±34.3 °C
Exact Mass 372.138031
LogP 3.52
Vapour Pressure 0.0±1.9 mmHg at 25°C
Index of Refraction 1.577
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.